In light of the COVID crisis, investors are re-examining how to measure companies’ sustainability performance. This article is based on research and conversations with investors, ESG and pharma industry experts.

Companies will need to continuously monitor changes in ESG rating frameworks and shifts in investors’ expectations. Although developments spurred by the pandemic are highly dynamic, we have ventured to take a brief snapshot of the trends that seem most significant for the pharmaceutical industry. This article outlines the main trends to watch post-COVID.